Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Societe Francophone de Greffe de Moelle et de Therapie Cellula
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Societe Francophone de Greffe de Moelle et de Therapie Cellula |
Type de publication | Journal Article |
Year of Publication | 2018 |
Auteurs | Decroocq J, Itzykson R, Vigouroux S, Michallet M, Yakoub-Agha I, Huynh A, Beckerich F, Suarez F, Chevallier P, Nguyen-Quoc S, Ledoux M-P, Clement L, Hicheri Y, Guillerm G, Cornillon J, Contentin N, Carre M, Maillard N, Mercier M, Mohty M, Beguin Y, Bourhis J-H, Charbonnier A, Dauriac C, Bay J-O, Blaise D, Deconinck E, Jubert C, Raus N, de Latour RPeffault, Dhedin N |
Journal | AMERICAN JOURNAL OF HEMATOLOGY |
Volume | 93 |
Pagination | 416-423 |
Date Published | MAR |
Type of Article | Article |
ISSN | 0361-8609 |
Résumé | {Patients with acute myeloid leukemia (AML) in relapse or refractory to induction therapy have a dismal prognosis. Allogeneic hematopoietic stem cell transplantation is the only curative option. In these patients, we aimed to compare the results of a myeloablative transplant versus a sequential approach consisting in a cytoreductive chemotherapy followed by a reduced intensity conditioning regimen and prophylactic donor lymphocytes infusions. We retrospectively analyzed 99 patients aged 18-50 years, transplanted for a refractory (52%) or a relapsed AML not in remission (48%). Fifty-eight patients received a sequential approach and 41 patients a myeloablative conditioning regimen. Only 6 patients received prophylactic donor lymphocytes infusions. With a median follow-up of 48 months, 2-year overall survival was 39%, 95% confidence interval (CI) (24-53) in the myeloablative group versus 33%, 95% CI (21-45) in the sequential groups (P=.39), and 2-year cumulative incidence of relapse (CIR) was 57% versus 50% respectively (P=.99). Nonrelapse mortality was not higher in the myeloablative group (17% versus 15% |
DOI | 10.1002/ajh.25004 |